Pharma BD Deal Intelligence

Merck & Co. Inc. / Seagen Inc.

2020 · Licensing/Option · $4.2B · Complete

Announcement Sentiment

100

Strongly positive

Outcome Score

Did not work — the deal failed to deliver.

Merck and Seattle Genetics (now Seagen) formed two strategic oncology collaborations. Merck paid $600M upfront and made a $1B equity investment for global co-development/co-commercialization of ladiratuzumab vedotin (LIV-1 targeting ADC), with up to $2.6B in milestones. Separately, Merck licensed TUKYSA (tucatinib) for HER2+ cancers in Asia, Middle East, LatAm.

Key facts

Announced Sep 14, 2020
Deal value $4.2B
Deal type Licensing/Option
Therapeutic area Oncology
Indications Triple-Negative Breast Cancer, HR+ Breast Cancer, HER2+ Cancers
Key assets Ladiratuzumab vedotin, TUKYSA (tucatinib)
Mechanism LIV-1 targeting ADC, HER2 tyrosine kinase inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals